FDA Accepts Wockhardt’s NDA for Breakthrough Antibiotic Zaynich, Marking Historic First for Indian Pharma
Wockhardt Ltd has announced that the US Food and Drug Administration has formally accepted the New Drug Application (NDA) for its novel, first‑in‑class antibiotic Zaynich, a milestone that positions the company as the first Indian drug maker to have an NCE‑based NDA filed and accepted by the US regulator. Filed on September 30, 2025, the application’s acceptance and Fast Track designation underscore Zaynich’s potential to address urgent, unmet medical needs, particularly life‑threatening infections caused by highly resistant Gram‑negative pathogens, where it has already shown life‑saving benefit under compassionate use in critically ill patients in India and the United States.
Built on a novel β‑lactam enhancer mechanism, Zaynich has drawn international attention for its strong activity against multidrug‑resistant hospital pathogens that drive prolonged hospitalisation and high mortality worldwide. Over more than a decade, starting from a science‑driven anti‑infective discovery programme launched in 2011, Wockhardt has developed Zaynich through extensive non‑clinical, clinical and regulatory work, making it one of the most comprehensively studied new antibiotics globally and highlighting India’s growing innovation capabilities in advanced drug development.
